TrialSignal transduction and targeted therapy2025

Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study.

Jindong Sheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.